triple negative breast cancer; (ER-, PR-, HER2-)

From Aaushi
Jump to navigation Jump to search

Laboratory

Management

More general terms

References

  1. 1.0 1.1 1.2 1.3 Medical Knowledge Self Assessment Program (MKSAP) 17, 18. American College of Physicians, Philadelphia 2015, 18.
  2. 2.0 2.1 FDA Approval Notice. March 8, 2019 FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm633065.htm